Christopher Nelson
Acute Care · Aberdeen, SDNPI 1720376825
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.4%. Reporting peaked in 2022 at $95,457 and has fallen 57.5% since, to $40,558 in 2025.
Across 550 payments — averaging $561.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$66K
- Amgen$49K
- Rigel Pharmaceuticals, Inc.$39K
- Beigene USA, Inc.$37K
- E.r. Squibb & Sons, L.L.C.$33K
- Johnson & Johnson$28K
- plus $57K from 28 others
What the payments were for
- Consulting fees$25,0078%
- Speaking & faculty fees$177,78158%
- Travel & lodging$98,35432%
- Food & beverage$7,2672%
- Education$6060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 124 | $66,237 |
| Amgen | 77 | $49,194 |
| Rigel Pharmaceuticals, Inc. | 56 | $38,796 |
| Beigene USA, Inc. | 50 | $37,239 |
| E.r. Squibb & Sons, L.L.C. | 55 | $32,535 |
| Johnson & Johnson | 41 | $28,413 |
| AstraZeneca(2 entities) | 28 | $17,863 |
| AbbVie | 25 | $10,410 |
| Bristol Myers Squibb | 18 | $8,150 |
| Gilead | 14 | $7,255 |
| Hologic Sales And Service, LLC | 1 | $4,410 |
| Epizyme, Inc. | 6 | $3,264 |
| Merck | 12 | $3,224 |
| Sanofi | 3 | $676 |
| Daiichi Sankyo Inc. | 2 | $200 |
| TG Therapeutics, Inc. | 1 | $185 |
| Astellas Pharma US Inc | 4 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $117 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Pfizer | 5 | $95 |
| Novartis | 5 | $90 |
| Caris MPI, Inc. | 1 | $58 |
| AVEO Pharmaceuticals, Inc. | 3 | $55 |
| Eisai Inc. | 3 | $53 |
| Iovance Biotherapeutics, Inc. | 2 | $47 |
| Myriad Genetic Laboratories, Inc. | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $16 |
| Array Biopharma Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few acute care providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 38 | $657,288 |
| BrukinsaZanubrutinib | 50 | $602,661 |
| CalquenceAcalabrutinib Maleate | 18 | $258,756 |
| ImbruvicaIbrutinib | 14 | $229,490 |
| ErleadaApalutamide | 14 | $209,564 |
| XtandiEnzalutamide | 16 | $203,726 |
| BraftoviEncorafenib | 12 | $179,441 |
| TagrissoOsimertinib Mesylate | 11 | $163,148 |
| MektoviBinimetinib | 11 | $161,384 |
| VotrientPazopanib Hcl | 11 | $131,954 |
| Enoxaparin Sodium | 18 | $8,513 |
| Liothyronine Sodium | 96 | $2,938 |
| Potassium Chloride | 122 | $2,647 |
| Anagrelide Hcl | 13 | $1,518 |
| Sucralfate | 41 | $1,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $8,150 | $657,28838 claims |
| Beigene USA, Inc.Brukinsa | $37,239 | $602,66150 claims |
| AstraZenecaCalquence, Tagrisso | $17,863 | $421,90329 claims |
| Array Biopharma IncBraftovi, Mektovi | $16 | $340,82523 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $27 | $229,49014 claims |
| Johnson & JohnsonErleada | $28,413 | $209,56414 claims |
| Astellas Pharma US IncXtandi | $142 | $203,72616 claims |
| NovartisVotrient | $90 | $131,95411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few acute care providers in South Dakotaon file to place this against a meaningful peer group, so we don't.
Other acute care in Aberdeen
- Wylie BarnesAberdeen$566
- Paulette NankivelRapid City$5K
- Jessica TvedtRapid City$3K
- Mikayla CrockerRapid City$3K
- Kali HuiskesSioux Falls$2K
- Ashley HeupelSioux Falls$1K
- Lonny HeinemannSioux Falls$187
- Katelyn BauerSioux Falls$164
- Jamie van LentSioux Falls$160
- Wade SendelbachSioux Falls$156
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.